Characterization of platelet function in cyclic hematopoietic dogs.
Platelet aggregation to incremental doses of eight different platelet agonists (collagen, thrombin, platelet-activating factor [PAF], arachidonic acid [AA] plus epinephrine, the calcium ionophore A23187, ADP, phospholipase C [PLC], and 12-O-tetradecanoyl phorbol-13-acetate [TPA]) was compared in normal (N) and cyclic hematopoietic (CH) dogs. Platelet aggregation was defective with collagen, PAF, TPA, and possibly thrombin as agonists but normal when ADP, PLC, arachidonic acid plus epinephrine, and A23187 were used as agonists with CH platelets. In heterozygous CH dogs, platelet aggregation was intermediately defective when tested with collagen and PAF as agonists. Thromboxane B2 (TXB2) concentrations (mean +/- SD; pg/10(6) platelets), as measured by RIA, were similar in CH and normal dogs both prior to (CH: 7.6 +/- 7.0; N: 5.5 +/- 3.9) and after collagen stimulation (collagen: 141.3 +/- 42.5; 123.1 +/- 38.4). Granule storage pools of serotonin and platelet adenine nucleotides were markedly decreased in homozygous CH but not heterozygous CH dogs. Thrombin stimulated phosphorylation of 40- and 20-kd proteins in platelets from CH and normal dogs to an equal extent. However, collagen-stimulated phosphorylation of the 40- but not the 20-kd protein was significantly decreased in platelets from CH dogs. These data suggest that there is a biochemical defect in platelets from CH dogs that results in storage pool disease and decreased phosphorylation of a 40-kd protein.
Lothrop
C D
CD
University of Tennessee Department of Environmental Practice, College of Veterinary Medicine 37901-1071.
Candler
R V
RV
Pratt
H L
HL
Urso
I M
IM
Jones
J B
JB
Carroll
R C
RC
D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D004283:Dog Diseases / Q000097:blood*; D004285:Dogs; D005260:Female; D006410:Hematopoiesis; D006579:Heterozygote; D008297:Male; D009503:Neutropenia / Q000097:blood / Q000662:veterinary*; D010507:Periodicity; D010766:Phosphorylation; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010981:Platelet Storage Pool Deficiency / Q000097:blood / Q000662:veterinary; D013917:Thrombin / Q000494:pharmacology; D010738:Type C Phospholipases / Q000494:pharmacology
D001798:Blood Proteins; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D010738:Type C Phospholipases; D013917:Thrombin